Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 17, Issue 2, Pages 296-302
Publisher
Oxford University Press (OUP)
Online
2014-07-23
DOI
10.1093/neuonc/nou146
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis
- (2014) Daichi Fujimoto et al. CLINICAL & EXPERIMENTAL METASTASIS
- EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?
- (2014) L.E.L. Hendriks et al. LUNG CANCER
- The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers
- (2013) Benjamin Izar et al. ANNALS OF THORACIC SURGERY
- A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer
- (2013) K. L. Johung et al. CLINICAL CANCER RESEARCH
- Determinants of Survival in Advanced Non–Small-Cell Lung Cancer in the Era of Targeted Therapies
- (2013) Joshua Bauml et al. Clinical Lung Cancer
- Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase–Rearranged Non–Small Cell Lung Cancer
- (2013) B Solomon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- KRASMutation: Should We Test for It, and Does It Matter?
- (2013) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association ofKRASandEGFRmutations with survival in patients with advanced lung adenocarcinomas
- (2012) Melissa L. Johnson et al. CANCER
- Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
- (2012) Robert C. Doebele et al. CANCER
- EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer
- (2012) Marco Bartolotti et al. Expert Review of Anticancer Therapy
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: A case report
- (2012) Alexander T. Falk et al. LUNG CANCER
- EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases
- (2012) Hsin-Lun Lee et al. Radiation Oncology
- Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer
- (2011) June Koo Lee et al. CANCER
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain
- (2011) M. Jamal-Hanjani et al. CLINICAL CANCER RESEARCH
- Effective Use of Thalidomide in the Treatment of Recurrent Metastatic Chordoma
- (2011) Wen Yee Chay et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
- (2011) Wolfram Brugger et al. JOURNAL OF CLINICAL ONCOLOGY
- Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
- (2011) Paul W. Sperduto et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor
- (2011) Britta Weber et al. Journal of Thoracic Oncology
- EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR
- (2011) Shang-Gin Wu et al. Journal of Thoracic Oncology
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
- (2010) Dora Dias-Santagata et al. EMBO Molecular Medicine
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer
- (2010) A. F. Eichler et al. NEURO-ONCOLOGY
- Evidence-Based Guidelines for the Management of Brain Metastases
- (2010) Sandeep S. Bhangoo et al. NEUROSURGERY CLINICS OF NORTH AMERICA
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- (2008) Marc Ladanyi et al. MODERN PATHOLOGY
- A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database
- (2007) Paul W. Sperduto et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now